Do we really not need high-volume hemofiltration?

doi:10.3877/cma.j.issn.2096-1537.2017.01.014

Abstract

Abstract:

High-volume hemofiltration (HVHF) can improve hemodynamics, organ dysfunction and outcome through removing inflammatory factors in critically ill patients. HVHF has been one of the adjuvant therapies for systemic inflammatory response syndrome such as sepsis and septic shock. However, there is still lack of randomized clinical trial (RCT) evidence about whether HVHF can improve survival or not in critically ill patients. Therefore, clinicians should carefully interpret the results of current clinical studies and balance the benefits and harms of HVHF when selecting the mode and dose of renal replacement therapy.

Key words: High-volume hemofiltration, Systemic inflammatory response syndrome, Sepsis, Continuous renal replacement therapy

Ruoming Tan, Hongping Qu. Do we really not need high-volume hemofiltration?[J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2017, 03(01): 65-68.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://icu.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-1537.2017.01.014

https://icu.cma-cmc.com.cn/EN/Y2017/V03/I01/65

References 17

[1]	Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial[J]. Lancet, 2000, 356(9223): 26–30.
[2]	Joannes-Boyau O, Honoré PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial[J]. Intensive Care Med, 2013, 39(9):1535–1546.
[3]	Lehner GF, Wiedermann CJ, Joannidis M. High-volume hemofiltration in critically ill patients: a systematic review and meta-analysis[J]. Minerva Anestesiol, 2014, 80(5):595–609
[4]	Clark E, Molnar AO, Joannes-Boyau O, et al. High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis[J]. Crit Care, 2014, 18(1):R7.
[5]	Honoré PM, Jacobs R, Boer W, et al. New insights regarding rationale, therapeutic target and dose of hemofiltration and hybrid therapies in septic acute kidney injury[J]. Blood Purif, 2012, 33 (1-3): 44–51.
[6]	Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis[J]. Artif Organs, 2003, 27(9): 792–801.
[7]	Honoré PM, Joannes-Boyau O. High volume hemofiltration (HVHF) in sepsis: a comprehensive review of rationale, clinical applicability, potential indications and recommendations for future research[J]. Int J Artif Organs, 2004, 27(12): 1077–1082.
[8]	Di Carlo JV, Alexander SR. Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis[J]. Int J Artif Organs, 2005, 28(8): 777–786.
[9]	VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, et al. . Intensity of renal support in critically ill patients with acute kidney injury[J]. N Engl J Med, 2008, 359(1): 7–20.
[10]	RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, et al. . Intensity of continuous renal-replacement therapy in critically ill patients[J]. N Engl J Med, 2009, 361(17): 1627–1638.
[11]	Ghani RA, Zainudin S, Ctkong N, et al. Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration[J]. Nephrology (Carlton), 2006, 11(5): 386–393.
[12]	Boussekey N, Chiche A, Faure K, et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock[J]. Intensive Care Med, 2008, 34(9): 1646–1653.
[13]	Jiang HL, Xue WJ, Li DQ, et al. Influence of continuous veno-venous hemofiltration on the course of acute pancreatitis[J]. World J Gastroenterol, 2005, 11(31): 4815–4821.
[14]	Rimmelé T, Wey PF, Bernard N, et al. Hemofiltration with the Cascade system in an experimental porcine model of septic shock[J]. Ther Apher Dial, 2009, 13:63–70.
[15]	Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial[J]. JAMA, 2009, 301(23): 2445–2452.
[16]	Rimmelé T, Assadi A, Cattenoz M, et al. High-volume hemofiltration with a new hemofiltration membrane having enhanced adsorption properties in septic pigs[J]. Nephrol Dial Transplant, 2009, 24(2):421–427.
[17]	Joannes-Boyau O, Honoré PM, Boer W, et al. Are the synergistic effects of high-volume hemofiltration and enhanced adsorption the missing key in sepsis modulation?[J]. Nephrol Dial Transplant, 2009, 24(2): 354–357.

Please choose a citation manager

Content to export